专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110152189A1 METHODS FOR THE INHIBITION OF SCARRING 审中-公开
标题翻译：抑制扫描的方法
公开(公告)号：US20110152189A1
公开(公告)日：2011-06-23
申请号：US13003755
申请日：2008-12-11
申请人： Mark William James Ferguson , Sharon O'Kane , Tracey Mason , Mark Cooper , Nick Occleston , David Fairlamb , James Bush
发明人： Mark William James Ferguson , Sharon O'Kane , Tracey Mason , Mark Cooper , Nick Occleston , David Fairlamb , James Bush
IPC分类号： A61K38/18 , A61P17/02
CPC分类号： A61K38/1841 , A61K9/0019 , A61K9/0021 , A61K38/00
摘要： The invention provides new methods of treatment using TGF-β3 to inhibit scarring in humans, and TGF-β3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment each centimetre of wound margin, or each centimetre of a site at which a wound is to be formed, is provided with between approximately 350 ng and 1000 ng of TGF-β3; and in a second incidence of treatment, occurring after a wound is formed, and between 8 and 48 hours after the first incidence of treatment, the wound is provided with an amount of between approximately 350 ng and 1000 ng of TGF-β3 per centimetre of wound margin in which scarring is to be inhibited. The amount of TGF-β3 provided may be the same in each incidence of treatment. The amount of TGF-β3 provided per centimetre in each incidence of treatment may preferably be approximately 500 ng. The TGF-β3 may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound.
摘要翻译：本发明提供使用TGF-β3抑制人类瘢痕形成的新治疗方法，以及用于抑制人瘢痕形成的新用途的TGF-β3。在第一次治疗发生率中，每厘米的伤口边缘或要形成伤口的部位的每厘米处提供约350ng至1000ng的TGF-β1; 并且在第一次治疗发生后，在伤口形成之后发生，并且在第一次治疗后8至48小时之间，所述伤口被提供有大约350ng和1000ng之间的TGF-和bgr 3 伤口边缘的厘米，其中瘢痕形成被抑制。所提供的TGF-β1的量可以在每次治疗发生率中相同。在每次治疗发生率中每厘米提供的TGF-β1,3的量优选为约500ng。 TGF-β可以通过皮内注射来提供。还提供了选择用于抑制与人类伤口愈合相关的瘢痕形成的适当治疗方案的试剂盒和方法。

2. 发明申请

US20100266532A1 METHODS FOR INHIBITING SCARRING 审中-公开
标题翻译：抑制扫描的方法
公开(公告)号：US20100266532A1
公开(公告)日：2010-10-21
申请号：US12747656
申请日：2008-12-11
申请人： Mark William James FERGUSON
发明人： Mark William James FERGUSON
IPC分类号： A61K38/20 , C07K14/54 , A61P17/02 , B65D71/00
CPC分类号： A61K38/2066
摘要： The invention provides new methods of treatment using anti-scarring agents to inhibit scarring in humans, and also provides anti-scarring agents for new uses in the inhibition of scarring in humans. In a first incidence of treatment an anti-scarring agent is provided to each centimetre of a wound margin or each centimetre of a site at which a wound is to be formed in a first therapeutically effective amount; and in a subsequent incidence of treatment the anti-scarring agent is provided to each centimetre of wound margin in a larger therapeutically effective amount. The incidences of treatment occur between 8 hours and 48 hours apart from one another. The anti-scarring agent is preferably not TGF-β3. The anti-scarring agent may be provided by intradermal N injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound.
摘要翻译：本发明提供使用抗瘢痕形成剂抑制人类瘢痕形成的新治疗方法，并且还提供抗瘢痕形成剂用于抑制人瘢痕形成的新用途。在第一次治疗中，将抗瘢痕形成剂提供给每个厘米的伤口边缘或每厘米的伤口以第一治疗有效量形成的部位; 并且在随后的治疗发生中，以更大的治疗有效量将抗瘢痕形成剂提供给每厘米的伤口边缘。治疗的发生发生在彼此之间8小时至48小时之间。抗瘢痕形成剂优选不是TGF-β; 3。抗瘢痕形成剂可以通过皮内N注射来提供。还提供了选择用于抑制与人类伤口愈合相关的瘢痕形成的适当治疗方案的试剂盒和方法。

3. 发明授权

US07700562B2 Use of —furin—“convertase” inhibitors in the treatment of fibrosis and scarring 失效
标题翻译：使用-furin-“转化酶”抑制剂治疗纤维化和瘢痕形成
公开(公告)号：US07700562B2
公开(公告)日：2010-04-20
申请号：US10522222
申请日：2003-07-23
申请人： Mark William James Ferguson , Georg Brunner
发明人： Mark William James Ferguson , Georg Brunner
IPC分类号： A61K38/06 , A61F13/00 , A61D9/00
CPC分类号： A61K38/07 , A61K38/08 , A61K38/55 , A61K48/00
摘要： The present invention relates to use of convertase inhibitors for the reduction of scarring during the healing of wounds and also for reducing fibrosis in the treatment of fibrotic conditions.
摘要翻译：本发明涉及转化酶抑制剂在伤口愈合期间减少瘢痕形成的用途，并且还涉及在纤维化病症治疗中减少纤维化。

4. 发明申请

US20090305279A1 METHOD OF DIAGNOSIS 审中-公开
标题翻译：诊断方法
公开(公告)号：US20090305279A1
公开(公告)日：2009-12-10
申请号：US12439278
申请日：2007-08-28
申请人： Mark William James Ferguson , Hugh Gerald Laverty , Nicholas Occleston , Sharon O'Kane , Darren Hodgson , Neil French , Claire Cridland , Philip Roby , Ardeshir Bayat
发明人： Mark William James Ferguson , Hugh Gerald Laverty , Nicholas Occleston , Sharon O'Kane , Darren Hodgson , Neil French , Claire Cridland , Philip Roby , Ardeshir Bayat
IPC分类号： C12Q1/68 , C40B40/06 , C40B40/10
CPC分类号： C12Q1/6881 , C12Q1/6883 , C12Q2600/106 , C12Q2600/158
摘要： Provided are methods, kits and arrays for use in determining whether a scar of interest is keloid or non-keloid in nature. These determine keloid or non-keloid nature based on comparison of gene expression in the scar of interest with expression in a control sample. If expression of at least one gene, selected from the group of genes set out in Table 1, is decreased in a sample representative of gene expression in the scar of interest compared to expression of the same gene (or genes) in the control sample this indicates that the scar of interest comprises a keloid.
摘要翻译：提供了用于确定感兴趣的瘢痕是瘢痕疙瘩还是非瘢痕疙瘩的方法，试剂盒和阵列。这些基于对照样品中感兴趣的瘢痕中的基因表达与表达的比较来确定瘢痕疙瘩或非瘢痕疙瘩性质。与对照样品中相同基因（或基因）的表达相比，表达选自表1所示基因组中的至少一种基因的表达在表达感兴趣的瘢痕中的基因表达的样品中降低表示感兴趣的瘢痕包括瘢痕疙瘩。

5. 发明申请

US20090137475A1 MEDICAMENTS AND PROTEINS BASED ON TGF-BETA MONOMERS FOR THE TREATMENT OF WOUNDS 失效
标题翻译：基于TGF-beta单体治疗创伤的药物和蛋白质
公开(公告)号：US20090137475A1
公开(公告)日：2009-05-28
申请号：US12282472
申请日：2007-03-12
申请人： Mark William James Ferguson , Phillip Mellor , Hugh Gerard Laverty , Nick Occleston , Sharon O'Kane , Emma Atkinson
发明人： Mark William James Ferguson , Phillip Mellor , Hugh Gerard Laverty , Nick Occleston , Sharon O'Kane , Emma Atkinson
IPC分类号： A61K38/18 , A61P17/02
CPC分类号： A61K38/1841
摘要： There is provided the use of monomeric TGF-βs, or there fragments or derivatives, as medicaments. These medicaments preferably comprise monomeric TGF-β3, or fragments or derivatives thereof. The medicaments provided may be used in the acceleration of wounding and/or the inhibition of scarring, in the promotion of epithelial regeneration, or in the prevention and/or treatment of fibrotic disorders.
摘要翻译：提供单体TGF-β或使用片段或衍生物作为药物的用途。这些药物优选包含单体TGF-β3或其片段或衍生物。所提供的药物可用于加速伤口和/或抑制瘢痕形成，促进上皮再生，或预防和/或治疗纤维化疾病。

6. 发明授权

US07332305B2 Genetic polymorphism in the Zf9 gene linked to inappropriate scarring or fibrosis 失效
标题翻译： Zf9基因遗传多态性与不适当的瘢痕或纤维化有关
公开(公告)号：US07332305B2
公开(公告)日：2008-02-19
申请号：US10469609
申请日：2002-03-01
申请人： Mark William James Ferguson , William Ernest Royce Ollier , Ardeshir Bayat
发明人： Mark William James Ferguson , William Ernest Royce Ollier , Ardeshir Bayat
IPC分类号： C12P19/34
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention relates to an in vitro method for diagnosing or detecting a predisposition to a condition at least partially characterised by inappropriate fibrosis or scarring (e.g. Dupuytren's Disease). The method comprises examining the ZF9 gene, and regulatory elements thereof, derived from a subject of interest to detect the presence of a genetic poylmorphism or mutation in said gene which is linked with the condition.
摘要翻译：本发明涉及用于诊断或检测至少部分地表征为不适当的纤维化或瘢痕形成（例如Dupuytren氏病）的病症的倾向的体外方法。该方法包括检查衍生自感兴趣的受试者的ZF9基因及其调控元件，以检测与该病症相关的所述基因中遗传多态性或突变的存在。

7. 发明授权

US06331298B1 Wound healing and treatment of fibrotic disorders 失效
标题翻译：伤口愈合和治疗纤维化疾病
公开(公告)号：US06331298B1
公开(公告)日：2001-12-18
申请号：US08307640
申请日：1994-09-16
申请人： Mark William James Ferguson , Mamta Shah
发明人： Mark William James Ferguson , Mamta Shah
IPC分类号： A61K4500
CPC分类号： A61K38/1841 , A61K38/1709 , A61K38/179 , A61K38/1825 , A61K39/395 , A61K38/18 , A61K2300/00
摘要： A healing composition containing at least one non-fibrotic growth factor in combination with a pharmaceutically acceptable carrier is disclosed. A method of preparation of the composition and method of treating a host, suffering from a wound or fibrotic condition, disease, disorder with the composition is also disclosed.
摘要翻译：公开了包含与药学上可接受的载体组合的至少一种非纤维化生长因子的愈合组合物。还公开了用该组合物治疗患有伤口或纤维化病症的疾病，病症的宿主的组合物和方法的制备方法。

8. 发明授权

US6140307A Pharmaceutical composition 失效
标题翻译：药物组成
公开(公告)号：US6140307A
公开(公告)日：2000-10-31
申请号：US11138
申请日：1998-05-29
申请人： Mark William James Ferguson , Sarah Glenys Moore , Sally Freeman
发明人： Mark William James Ferguson , Sarah Glenys Moore , Sally Freeman
IPC分类号： C07H7/02 , A61K31/00 , A61K31/70 , A61K31/7024 , A61P17/00 , A61P17/02 , C07H11/04 , C07H15/00
CPC分类号： A61K31/7024 , A61K31/70 , C07H11/04
摘要： The present invention concerns analogues of mannose-6-phosphate for use in promoting the healing of wounds or fibrotic disorders with reduced scarring, and methods for doing same.
摘要翻译： PCT No.PCT / GB96 / 01840 Sec。 371日期：1998年5月29日 102（e）日期1998年5月29日PCT提交1996年7月31日PCT公布。公开号WO97 / 05883 日期1997年2月20日本发明涉及用于促进伤口愈合或减少瘢痕形成的纤维化病症的甘露糖-6-磷酸酯的类似物，以及用于进行其的方法。

9. 发明授权

US6093388A Mannose-6-phosphate composition and its use in treating fibrotic disorders 有权
标题翻译：甘露糖-6-磷酸酯组合物及其在治疗纤维化疾病中的应用
公开(公告)号：US6093388A
公开(公告)日：2000-07-25
申请号：US243531
申请日：1999-02-03
申请人： Mark William James Ferguson
发明人： Mark William James Ferguson
IPC分类号： A61F13/00 , A61K31/74
CPC分类号： A61K31/7024
摘要： Mannose-6-phosphate is formulated by pH adjustment as a suspension or solution at pH 6 to 8, preferably 6.5 to 7.5 and preferably at a concentration of 65 to 300 mM. Suspensions can be made in viscous hyaluronic acid gels. These compositions are useful in wound healing, particularly to prevent or mitigate scar formation.
摘要翻译：甘露糖-6-磷酸通过pH调节作为悬浮液或溶液配制，pH6至8，优选6.5至7.5，优选浓度为65至300mM。悬浮液可以在粘性透明质酸凝胶中制成。这些组合物可用于伤口愈合，特别是用于预防或减轻瘢痕形成。

10. 发明授权

US5662904A Anti-scarring compositions comprising growth factor neutralizing antibodies 失效
标题翻译：包含生长因子中和抗体的抗瘢痕组合物
公开(公告)号：US5662904A
公开(公告)日：1997-09-02
申请号：US122508
申请日：1993-09-27
申请人： Mark William James Ferguson , David Michael Foreman , Mamta Shah
发明人： Mark William James Ferguson , David Michael Foreman , Mamta Shah
IPC分类号： A61K9/06 , A61K9/08 , A61K9/107 , A61K9/12 , A61K9/14 , A61K9/52 , A61K9/70 , A61K31/70 , A61K31/711 , A61K38/00 , A61K38/18 , A61K38/19 , A61K39/395 , A61K45/00 , A61K47/48 , A61K48/00 , A61P17/00 , A61P17/02 , A61P43/00 , C07K14/71 , C07K16/22 , A61K39/44 , C07K17/04
CPC分类号： C07K14/71 , C07K16/22 , A61K38/00
摘要： A composition for use in the treatment of wounds to inhibit scar tissue formation during healing, comprising an effective amount of an activity-inhibiting growth factor neutralizing agent or agents specific against all TGF-.beta., except for TGF-.beta..sub.3, and PDGF, together with a pharmaceutically acceptable carrier. A method of preparing the composition and a method of administering the composition to a host suffering from tissue wounding is also disclosed.
摘要翻译： PCT No.PCT / GB92 / 00570 Sec。 371日期：1993年9月27日 102（e）日期1993年9月27日PCT 1991年3月30日PCT公布。出版物WO92 / 17206 日期1992年10月15日用于治疗创伤以抑制愈合期间瘢痕组织形成的组合物，包含有效量的活性抑制生长因子中和剂或除TGF-β3以外的所有TGF-β特异性试剂，和PDGF，以及药学上可接受的载体。还公开了制备组合物的方法和将组合物给予组织伤口的宿主的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式